{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:17:14Z","timestamp":1787995034293,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10067-026-08305-6","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:20:03Z","timestamp":1785241203000},"page":"5503-5511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ivarmacitinib in patients with active ankylosing spondylitis: subgroup analysis based on key baseline features from a phase II\/III trial"],"prefix":"10.1007","volume":"45","author":[{"given":"Bei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yini","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiduo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-9380","authenticated-orcid":false,"given":"Jin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"10473","key":"8305_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","volume":"405","author":"V Navarro-Compan","year":"2025","unstructured":"Navarro-Compan V, Sepriano A, Capelusnik D et al (2025) Axial spondyloarthritis. Lancet 405(10473):159\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(24)02263-3","journal-title":"Lancet"},{"key":"8305_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113709","volume":"145","author":"Y Wei","year":"2025","unstructured":"Wei Y, Zhang S, Shao F et al (2025) Ankylosing spondylitis: from pathogenesis to therapy. Int Immunopharmacol 145:113709. https:\/\/doi.org\/10.1016\/j.intimp.2024.113709","journal-title":"Int Immunopharmacol"},{"key":"8305_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.996103","volume":"13","author":"Y Xiong","year":"2022","unstructured":"Xiong Y, Cai M, Xu Y et al (2022) Joint together: the etiology and pathogenesis of ankylosing spondylitis. Front Immunol 13:996103. https:\/\/doi.org\/10.3389\/fimmu.2022.996103","journal-title":"Front Immunol"},{"issue":"5","key":"8305_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.2024.20917","volume":"333","author":"M Bittar","year":"2025","unstructured":"Bittar M, Deodhar A (2025) Axial spondyloarthritis: a review. JAMA 333(5):408\u2013420. https:\/\/doi.org\/10.1001\/jama.2024.20917","journal-title":"JAMA"},{"issue":"1","key":"8305_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A et al (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82(1):19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"8305_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H et al (2021) Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 80(8):1004\u20131013. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219601","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8305_CR7","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J et al (2022) Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis 81(11):1515\u20131523. https:\/\/doi.org\/10.1136\/ard-2022-222608","journal-title":"Ann Rheum Dis"},{"issue":"10214","key":"8305_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/s0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL et al (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet 394(10214):2108\u20132117. https:\/\/doi.org\/10.1016\/s0140-6736(19)32534-6","journal-title":"Lancet"},{"issue":"8","key":"8305_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3899\/jrheum.2023-1198","volume":"51","author":"A Deodhar","year":"2024","unstructured":"Deodhar A, Baraliakos X, Magrey M et al (2024) Efficacy and safety of tofacitinib in ankylosing spondylitis by baseline C-reactive protein level: post hoc analysis of phase II and phase III clinical trials. J Rheumatol 51(8):772\u2013780. https:\/\/doi.org\/10.3899\/jrheum.2023-1198","journal-title":"J Rheumatol"},{"issue":"1","key":"8305_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40744-024-00726-6","volume":"12","author":"H Norton","year":"2025","unstructured":"Norton H, Sliwinska-Stanczyk P, Hala T et al (2025) Tofacitinib efficacy\/safety in patients with ankylosing spondylitis by baseline body mass index: a post hoc analysis of phase 2\/3 trials. Rheumatol Ther 12(1):67\u201384. https:\/\/doi.org\/10.1007\/s40744-024-00726-6","journal-title":"Rheumatol Ther"},{"issue":"12","key":"8305_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/acr2.11601","volume":"5","author":"A Deodhar","year":"2023","unstructured":"Deodhar A, Marzo-Ortega H, Wu J et al (2023) Tofacitinib efficacy and safety in patients with ankylosing spondylitis by prior biologic disease-modifying antirheumatic drug use: a post hoc analysis. ACR Open rheumatology 5(12):632\u2013643. https:\/\/doi.org\/10.1002\/acr2.11601","journal-title":"ACR Open rheumatology"},{"issue":"2","key":"8305_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard-2024-226385","volume":"84","author":"J Liu","year":"2025","unstructured":"Liu J, Jiang Y, Zhang S et al (2025) Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. Ann Rheum Dis 84(2):188\u2013200. https:\/\/doi.org\/10.1136\/ard-2024-226385","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8305_CR13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","volume":"163","author":"B Chen","year":"2022","unstructured":"Chen B, Zhong J, Li X et al (2022) Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase II study. Gastroenterology 163(6):1555\u20131568. https:\/\/doi.org\/10.1053\/j.gastro.2022.08.007","journal-title":"Gastroenterology"},{"key":"8305_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/art.43238","author":"X Liu","year":"2025","unstructured":"Liu X, Xu L, Zhao C et al (2025) Efficacy and safety of ivarmacitinib, a selective JAK1 inhibitor, in patients with active ankylosing spondylitis: results from an adaptive seamless phase 2\/3 trial. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.43238","journal-title":"Arthritis Rheumatol"},{"key":"8305_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152032","volume":"55","author":"D Benavent","year":"2022","unstructured":"Benavent D, Capelusnik D, van der Heijde D et al (2022) How is early spondyloarthritis defined in the literature? Results from a systematic review. Semin Arthritis Rheum 55:152032. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152032","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"8305_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/ar4055","volume":"14","author":"CG Saad","year":"2012","unstructured":"Saad CG, Ribeiro AC, Moraes JC et al (2012) Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 14(5):R216. https:\/\/doi.org\/10.1186\/ar4055","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"8305_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger N, van der Heijde D, Inman RD et al (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70(6):973\u2013981. https:\/\/doi.org\/10.1136\/ard.2010.147744","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8305_CR18","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1007\/s10067-022-06228-6","volume":"41","author":"H Marzo-Ortega","year":"2022","unstructured":"Marzo-Ortega H, Navarro-Compan V, Akar S et al (2022) The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis. Clin Rheumatol 41(11):3573\u20133581. https:\/\/doi.org\/10.1007\/s10067-022-06228-6","journal-title":"Clin Rheumatol"},{"issue":"1","key":"8305_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/acr.25048","volume":"75","author":"C Fernandez-Carballido","year":"2023","unstructured":"Fernandez-Carballido C, Sanchez-Piedra C, Valls R et al (2023) Female sex, age, and unfavorable response to tumor necrosis factor inhibitors in patients with axial spondyloarthritis: results of statistical and artificial intelligence-based data analyses of a national multicenter prospective registry. Arthritis Care Res (Hoboken) 75(1):115\u2013124. https:\/\/doi.org\/10.1002\/acr.25048","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8305_CR20","doi-asserted-by":"publisher","first-page":"1759720X2110307","DOI":"10.1177\/1759720X211030792","volume":"13","author":"L Hu","year":"2021","unstructured":"Hu L, Ji X, Wang Y et al (2021) Underweight and obesity are strong predictors of clinical outcomes in patients with ankylosing spondylitis: data from the Smart-phone SpondyloArthritis Management System. Ther Adv Musculoskelet Dis 13:1759720X211030792. https:\/\/doi.org\/10.1177\/1759720X211030792","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"8305_CR21","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s10067-020-05319-6","volume":"40","author":"PA Zurita Prada","year":"2021","unstructured":"Zurita Prada PA, Urrego Laurin CL, Guillen Astete CA et al (2021) Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review. Clin Rheumatol 40(5):1673\u20131686. https:\/\/doi.org\/10.1007\/s10067-020-05319-6","journal-title":"Clin Rheumatol"},{"issue":"9","key":"8305_CR22","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3899\/jrheum.160003","volume":"43","author":"J Braun","year":"2016","unstructured":"Braun J, Baraliakos X, Hermann KG et al (2016) Serum C-reactive protein levels demonstrate predictive value for radiographic and magnetic resonance imaging outcomes in patients with active ankylosing spondylitis treated with golimumab. J Rheumatol 43(9):1704\u20131712. https:\/\/doi.org\/10.3899\/jrheum.160003","journal-title":"J Rheumatol"},{"issue":"8","key":"8305_CR23","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC et al (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76(8):1340\u20131347. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210322","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08305-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08305-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08305-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:35:03Z","timestamp":1787992503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08305-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8305"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08305-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This was a post-hoc analysis from a phase II\/III trial (NCT04481139). The details of the phase II\/III trial were listed at\n                      \n                      . The original phase II\/III trial was approved by an institutional review board or independent ethic committee at each of the 51 study sites. All patients provided written informed consent.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}